RedHill Biopharma and IntelGenx submits NDA to FDA for RIZAPORT for Migraines
RedHill Biopharma together with IntelGenx announced that they have resubmitted the 505(b)(2) New Drug Application (NDA) for RIZAPORT 10mg to the U.S. Food and Drug Administration (FDA).…
Read More...
Read More...
